FDA Critical Path Office Would Define Up To Four “Opportunities” Per Year
This article was originally published in The Gray Sheet
Executive Summary
FDA envisions creating an Office of Critical Path Opportunities over the next few months to coordinate with industry, academics, clinicians and the general public in proposing an annual list of translational research priorities to spur product development
You may also be interested in...
FDA Workshop Weighs Breast Cancer Ablation Benefits, Trial Protocol Issues
Stakeholders debating appropriate feasibility study protocol for image-guided thermal ablation of early-stage breast cancer are cautioning that increased use of advanced imaging for the procedures may counter some of the anticipated cost benefits
FDA Workshop Weighs Breast Cancer Ablation Benefits, Trial Protocol Issues
Stakeholders debating appropriate feasibility study protocol for image-guided thermal ablation of early-stage breast cancer are cautioning that increased use of advanced imaging for the procedures may counter some of the anticipated cost benefits
FDA Science Board Previews Device “Critical Path” R&D Opportunity List
Peripheral vasculature imaging is poised to be an early beneficiary of FDA's "critical path" initiative, CDRH Office of Science & Engineering Director Larry Kessler told the agency's Science Board April 22